How does it feel to be on psilocybin? Dose-response relationships of subjective experiences in humans
OpenAlex – June 11, 2020
Source: OpenAlex
Summary
Higher doses of psilocybin, the potent hallucinogen, reliably intensify subjective psychological experiences. A comprehensive meta-analysis established a clear positive correlation between oral psilocybin dosage and ratings on scales like the Mystical Experience Questionnaire and Hallucinogen Rating Scale. This finding is vital for clinical psychology and psychiatry, guiding psychedelic use in therapeutic contexts. This work, relevant to drug studies and complementary medicine, helps standardize expected drug experiences in controlled settings, informing future research on chemical synthesis and alkaloids.
Abstract
Abstract Psilocybin is the active component of magic mushrooms and is well known for its psychoactive properties. Different questionnaires have been developed to systematically quantify altered states of consciousness induced by psychoactive drugs. The aim of this study was to obtain the dose-response relationships of the subjective experiences induced by psilocybin in healthy study participants. For this purpose, we applied a linear meta-regression approach on questionnaire ratings after oral administration of psilocybin in a controlled setting. Data was obtained from The Altered States Database, which contains psychometric data extracted from peer-reviewed articles published in MEDLINE-listed journals that used standardized and validated questionnaires. Our meta-analysis included data of the Altered States of Consciousness Rating Scale, the Mystical Experience Questionnaire (MEQ30), and the Hallucinogen Rating Scale (HRS). We used the Robust Variance Estimation Framework to obtain linear dose-response relationship estimates for each dimension of the given questionnaires. Ratings on most dimensions and subscales of the included questionnaires correlated positively with dose. Since subjective experiences are not only determined by dose, but also by individual differences and environmental factors, our results do not necessarily generalize to recreational use, as our analyses are based on data from controlled laboratory experiments. The paper at hand could serve as a general literature citation for the use of psilocybin in experimental and clinical research, especially for the comparison of expected and observed subjective drug experiences.